R&D expense · 2015–2025

Rhythm Pharmaceuticals R&D expense

$167M−29.7% · FY2025

Rhythm Pharmaceuticals (RYTM) reported $167M in R&D expense for fiscal 2025, −29.7% year on year.

$7.1M2015$19.6M2016$22.9M2017$50.3M2018$109M2019$90.5M2020$104M2021$109M2022$135M2023$238M2024$167M2025
Rhythm Pharmaceuticals — R&D expense, 2015–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$167M−29.7%Open →
FY20242024-12-31$238M+76.3%Open →
FY20232023-12-31$135M+24.2%Open →
FY20222022-12-31$109M+4.3%Open →
FY20212021-12-31$104M+15.1%Open →
FY20202020-12-31$90.5M−17.4%Open →
FY20192019-12-31$109M+117.4%Open →
FY20182018-12-31$50.3M+119.9%Open →
FY20172017-12-31$22.9M+16.8%Open →
FY20162016-12-31$19.6M+174.1%Open →
FY20152015-12-31$7.1M—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +37.1%

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Rhythm Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/rhythm-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Rhythm Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/rhythm-pharmaceuticals/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-rhythm-pharmaceuticals-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Rhythm Pharmaceuticals R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/rhythm-pharmaceuticals/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001628280-26-012399 · February 26, 2026

{{cite web |title=Rhythm Pharmaceuticals R&D expense — 10-K (0001628280-26-012399) |url=https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/rytm-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Rhythm Pharmaceuticals overview